SPT-320

SPT-320, also formerly known as LYT-320, is a prodrug of agomelatine which is under development for the treatment of mood and anxiety disorders, for instance generalized anxiety disorder.^[1][2]

SPT-320

Clinical data
Other names	SPT320; LYT-320; LYT320
Routes of administration	Oral[1]
Drug class	Melatonin receptor agonist; Serotonin 5-HT2B receptor antagonist; Serotonin 5-HT2C receptor antagonist;

As an agomelatine prodrug, it acts as a melatonin receptor agonist and as a serotonin 5-HT_2B and 5-HT_2C receptor antagonist.^[1][2] The drug is taken by mouth and is said to bypass first-pass hepatic metabolism.^[1][2]

As of December 2023, SPT-320 is in the preclinical research phase of development.^[1][2] It is under development by Seaport Therapeutics and is being developed towards approval in the United States.^[1][2] The chemical structure of SPT-320 does not yet appear to have been disclosed.^[1]